日达仙联合化疗治疗肺癌并胸腔积液30例临床观察_周建平.pdf

# 258 # HENAN JOURNAL OF ONCOLOGY Vol117 No14 Aug1 2004 日达仙联合化疗治疗肺癌并胸腔积液 30 例临床观察 周建平, 李伟阳, 黎松波 ( 东莞市人民医院心胸外科, 广东 东莞 523000) 摘要: 目的 观察日达仙联合化疗药物胸腔内 灌注对肺癌并胸腔积液的疗效。方法 采用胸腔置管引流灌 注顺铂及 皮下注射日 达 + + 仙与单用顺铂灌注疗效对照。结果 日达仙+ 顺铂组患者的临床总缓解率为 76167% 。NK 细胞活性及 CD4 / CD8 比值明显高于 治 + + 疗前; 单顺铂组 的临床总缓 解率为 461 60% , NK 细 胞活性及 CD4 / CD8 比值低 于治疗前。两 组治疗方 法有显著性 差异( P 0105) 。 结论 胸腔内灌注化疗药联用生物制剂日达仙, 疗效明显优于单纯胸腔 内灌注化 疗药, 并能改 善临床 症状, 提高免 疫功能, 为肺 癌 并胸腔积液有效治疗方法之一。 关键词: 日达仙; 生物治疗联合化疗; 肺癌并胸腔积液 中图分类号: R730158 文献标识码: A 文章编号: 1003- 1464( 2004) 04- 0258- 03 Combining Zadaxin and Systemic Chemotherapy in Treatment of 30 Cases of Lung Cancer with Hydrothorax Zhou Jianping, Li Weiyang, Li Songbo (The People. s Hospital of Dongguan, Dongguan 523000, China) Abstract: Objective To observe the therapeutic effect of combining Zadax in and systemic chemotherapy in perfusion of thoracic cavity in the cases of lung cancer with hydrothorax1 Methods The sixty patients were divided into two groups: combining Zadax in and DDP chemotherapy group and solo- DDP group, both groups was treated with thoracic cavity closed drainage before perfusion1Results The effective rate in treatment group was + + 761 67% , control group was 46160%